StrokeLASTENCT03811769
Large Stroke Therapy Evaluation
A study testing Best Medical Therapy and Mechanical Thrombectomy in people with Stroke, run by University Hospital, Montpellier at 1 site in France.
Trial summary
Stroke represents the fourth leading cause of death in industrialized nations, after heart disease, cancer, and chronic lower respiratory disease. The overall burden of stroke will rise dramatically in the next 20 years due to an ageing population. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke
- What is being tested?
- Best Medical Therapy and Mechanical Thrombectomy
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 335 participants
- Where
- 1 siteFrance
- Study dates
- 7 Apr 2019to 24 Aug 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject is ≥ 18 years old at inclusion (no upper age limit)
- Clinical signs consistent with acute ischemic stroke with symptoms onset or TLKW ≤ 6.5 hours from randomization, or with negative FLAIR on MRI if TLSW is unknown, with treatment started within 7 hours.
- Proven Large Ischemic Core defined as: ASPECT Score ≤ 5 on non-contrast CT or DWI-MRI, and in patients ≥ 80 years: ASPECT = 3 to 5 on non-contrast CT or DWI-MRI
- Proved anterior circulation intracranial large vessel occlusion on CTA or MRA (intracranial ICA, M1, M1-M2). The MCA - M1 segment is defined as the first branch of the intracranial ICA which courses horizontally from its branching point off the ICA through the Sylvian fissure up to the first bifurcation distal to the lenticulo-striate arteries, in the Sylvian fissure. M2 is defined as the portions of the MCA distal to the first bifurcation or trifurcation, but prior to the second bifurcation.
- Patient or patient's representative has received information about the study and has signed and dated the appropriate Informed Consent Form
- Selection imaging performed ≤ 3 hours before randomization
Show all 11Show fewer
- Anticipated possibility to start the procedure (arterial access) within 30 minutes after randomization
- Pre stroke mRS ≤ 1
- Subjects receiving antiaggregant and/or anticoagulant agents (at any mode of administration) within the last 24 hours from screening are eligible for participation.
- NIHSS > 6
- For patients for whom thrombolytic therapy, such as IV t-PA, is indicated, such treatment is initiated as soon as possible and within the accepted clinical guidelines as measured from stroke symptom onset.
Who cannot join
- Known absence of vascular access.
- Known contrast or endovascular product life-threatening allergy.
- Female who is known to be pregnant or lactating at time of admission
- Patient presents severe or fatal co-morbidities or life expectancy under 6 months that will likely interfere with the improvement or follow-up or that will render the procedure unlikely to benefit the patient.
- Patient unable to present or be available for follow-up.
- Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.
Show all 26Show fewer
- Evidence of vessel recanalization prior to randomization.
- Seizures at stroke onset if it makes the diagnosis of stroke doubtful and precludes obtaining an accurate baseline NIHSS assessment.
- Current participation in another investigational drug study.
- Suspicion of aortic dissection based on medical history, clinical evaluation or/and imaging.
- Major patients under guardianship.
- Blood glucose < 50 mg/dL or > 400 mg/dL
- Cr > 4.0 mg/dL, unless the patient is on dialysis
- Platelet count < 50000/uL
- INR > 3.0 or PTT > 3 times upper limit of normal (ULN)
- Imaging Exclusion Criteria:
- Isolated proximal cervical ICA occlusions or proximal cervical ICA occlusions with MCA-M1 or intracranial ICA occlusion requiring stent placement, and isolated M2 occlusions on the pre-randomization neuro-imaging
- Evidence of intracranial hemorrhage on CT/MRI
- Excessive tortuosity of cervical vessels on CTA/MRA that would likely result in unstable access platform
- High Suspicion of underlying intracranial stenosis on CTA/MRA/DSA
- Suspected cerebral vascular disease (e.g. vasculitis) based on medical history and CTA/MRA/DSA
- Presumed calcified Embolus or Intracranial Stenosis decompensation
- Intracranial stent implanted in the same vascular territory that would preclude the safe deployment/removal of the stentriever device
- Occlusions in multiple vascular territories (e.g.: bilateral anterior circulation, or anterior circulation/vertebrobasilar system) confirmed on CTA/MRA/DSA.
- Significant mass effect with midline shift as confirmed on CT/MRI
- Any ipsilateral cervical ICA lesion (Tandem), that requires stent placement
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Acute Mechanical Revascularisation in Large Stroke (ASPECTS 0-5) With Large Vessel Occlusion Within 7 Hours After Stroke Onset or Last Known Well
Stroke represents the fourth leading cause of death in industrialized nations, after heart disease, cancer, and chronic lower respiratory disease. The overall burden of stroke will rise dramatically in the next 20 years due to an ageing population. Approximately one-quarter of the patients suffering a stroke die within one year after the initial event and stroke is a leading cause of serious long-term disability. Acute ischemic stroke (AIS) due to large vessel occlusion (LVO) is a potentially devastating event, with a poor prognosis in the absence of timely revascularization. Whether in patients with large anterior circulation stroke, direct mechanical intervention is equally effective, superior or inferior to bridging thrombolysis remains a matter of debate.
Thus, this procedure, is now the recommended standard of care for selective patients with LVO in the anterior circulation. When performed with newer generation devices (mainly stent retrievers), more stringent imaging selection criteria and more efficient workflow than in previous trials, significantly reduces disability rates after AIS caused by LVO in the anterior circulation.
The STAIR (Stroke Treatment Academic Industry Roundtable) meeting aims to advance acute stroke therapy development through collaboration between academia, industry, and regulatory institutions. In pursuit of this goal and building on the available level I evidence of benefit from endovascular therapy (EVT) in large vessel occlusion stroke, STAIR IX consensus recommendations were developed that outline priorities for future research in EVT.
Read the detailed description
The LASTE hypothesis is that patient harbouring a large ischemic core stroke at presentation, may still benefit from mechanical thrombectomy, given the very poor natural history of patient managed by a standalone medical therapy.
The threshold of ASPECTS 5 to set a benefit for treatment was inspired by initial large medical trials using IV t-PA25-27 (Samurai-CT ALBERTA Score IV cohort). In the paradigm of acute and complete reperfusion, radiographic infarct stroke volume may be partially reversible and thus the resulting final infarct may be smaller compared to the one in non-re-perfused patients who will consequently have poorer clinical outcomes. By now, large core patients defined as ASPECTS 0-5 were excluded from most randomized clinical trials resulting in a lack of unequivocal evidence of benefit in this patient population.
Analyses of several prospective cohorts suggest signals of benefit in favor of thrombectomy in patients with large baseline core. In the prospective cohort ETIS, LAPERGUE et al reported a rate of good outcome of 34% in the subgroup of patient with ASPECT 4-5. In the prospective cohort analysis RECOST, a mean mRS score of 34% in a group of patient presenting ASPECT 0-5 treated with mechanical thrombectomy, versus 9% of good outcome in the medical group, suggesting a benefit to treat LVO harbouring a large core. The strongest argument in favor of benefit of EVT even in patients with large core is provided by the six completed randomized endovascular stroke trials. These trials did prove that Combined Approach Mechanical + IV t-PA, is superior to standalone IV lytics, mRs score ≤ 2 ranging from 33% and up to 72%, but Large Core Infarction were largely excluded. Nonetheless a pooled analysis of these trials revealed that a minority of patients with large baseline core were still randomized. In MR CLEAN study, despite no exclusion criteria defined in the initial protocol, the median ASPECT score of the cohort was 9 out of 10. In SWIFT-PRIME study, the mean ASPECT score of the cohort was 7, and in REVASCAT study it was 6.8.
The LASTE protocol "Large Stroke Therapy Evaluation" aims to study the efficacy and safety of mechanical thrombectomy in the acute phase of cerebral infarction less than 7 hours for patients with a large volume of necrosis defined by a score ASPECT from 0 to 5. The patients will be followed 6 months after the stroke.
- Conditions
- Stroke
- Being tested
- Best Medical Therapy, Mechanical Thrombectomy
- Keywords
- Mechanical thrombectomy, Stroke, Proximal intracranial arterial occlusions, Large vessel occlusion
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Best Medical TherapyOther
The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
Mechanical ThrombectomyProcedure or surgery
MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
| Study group | Role | What they receive |
|---|---|---|
| Best Medical Therapy (BMT) | Other | Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration Receives: Other: Best Medical Therapy |
| Mechanical Thrombectomy (MT) | Other | Endovascular treatment (thrombectomy) associated with the best medical treatment Receives: Procedure: Mechanical Thrombectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of patient's condition
Shift on the mRS at 90 days in experimental group vs the control group
Measured: 3 months
Secondary outcomes (8)
Evaluation of patient's condition
The degree of disability at 180 days (shift on the mRS combining scores of 5 and 6)
Measured: 6 months
Evaluation of good functional outcome
Rate of patients with a good functional outcome at 90 days and 180 days, defined as mRS 0-2
Measured: 3 and 6 months
Evaluation of functional outcome
Rate of patients with a favorable outcome at 90 and 180 days, defined as mRS 0-3
Measured: 3 and 6 months
Evaluation of treatment effect
Distribution of utility weighted mRS (UW mRS) at 90 and 180 days
Measured: 3 and 6 months
Evaluation of quality of life
Quality of life at 90 and 180 days assessed by EuroQol/EQ-5D
Measured: 3 and 6 months
Evaluation of decompressive condition
Rate of patients with secondary decompressive craniectomy within 7 days
Measured: 7 days
Evaluation of medical response
Rate of patients with "early good response" at Day 5-7/Discharge (whichever is earlier), defined as a NIHSS drop of ≥ 8 points from baseline or NIHSS score 0 or 1
Measured: Day 5-7 or discharge, whichever is earlier
Evaluation of medical condition
Change in infarct volumes on CT or MRI from baseline to 24 hours post randomization
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2019
- Study start7 Apr 2019
- Primary completion26 Apr 2023
- Study completion24 Aug 2023
Why it stopped: Although the planned sample size was 450, enrollment was halted early following an unplanned interim analysis recommended by the Data Safety Monitoring Board because results favoring thrombectomy were reported from other similar trials.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 335 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vincent COSTALAT, PU-PH, Principal investigator, Hôpital Gui de ChauliacCaroline ARQUIZAN, PH, Principal investigator, Hôpital Gui de ChauliacBertrand LAPERGUE, Principal investigator, Hôpital FochTudor JOVIN, PU-PH, Principal investigator, Cooper Neurological Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03811769
- Sponsor's protocol ID
- RECHMPL18_0173
- Acronym
- LASTE
- Status last verified
- Sep 2025
- First submitted
- 10 Jan 2019
- Last updated
- 29 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Cody JT. Cross-reactivity of amphetamine analogues with Roche Abuscreen radioimmunoassay reagents. J Anal Toxicol. 1990 Jan-Feb;14(1):50-3. doi: 10.1093/jat/14.1.50.
PubMed 2314063Costalat V, Jovin TG, Albucher JF, Cognard C, Henon H, Nouri N, Gory B, Richard S, Marnat G, Sibon I, Di Maria F, Annan M, Boulouis G, Cardona P, Obadia M, Piotin M, Bourcier R, Guillon B, Godard S, Pasco-Papon A, Eker OF, Cho TH, Turc G, Naggara O, Velasco S, Lamy M, Clarencon F, Alamowitch S, Renu A, Suissa L, Brunel H, Gentric JC, Timsit S, Lamy C, Chivot C, Macian-Montoro F, Mounayer C, Ozkul-Wermester O, Papagiannaki C, Wolff V, Pop R, Ferrier A, Chabert E, Ricolfi F, Bejot Y, Lopez-Cancio E, Vega P, Spelle L, Denier C, Millan M, Arenillas JF, Mazighi M, Houdart E, Del Mar Freijo M, Duhamel A, Sanossian N, Liebeskind DS, Labreuche J, Lapergue B, Arquizan C; LASTE Trial Investigators. Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size. N Engl J Med. 2024 May 9;390(18):1677-1689. doi: 10.1056/NEJMoa2314063.
PubMed 38718358Lapergue B, Arquizan C, Albucher JF, Cognard C, Henon H, Nouri N, Gory B, Richard S, Marnat G, Sibon I, Di Maria F, Annan M, Boulouis G, Cardona P, Labreuche J, Costalat V, Jovin TG; LASTE Trial Investigators. Endovascular Thrombectomy in Patients With Largest Baseline Infarcts (ASPECTS 0-2): An Ancillary Analysis of the LASTE Trial. Stroke. 2026 Jun;57(6):1504-1512. doi: 10.1161/STROKEAHA.125.054161. Epub 2026 Apr 14.
PubMed 41979451Gerschenfeld G, Lapergue B, Labreuche J, Albucher JF, Cognard C, Henon H, Nouri N, Richard S, Gory B, Sibon I, Marnat G, Van Dokkum L, Liebeskind DS, Jovin TG, Costalat V, Alamowitch S, Arquizan C; LASTE Trial Investigators. Efficacy and safety of bridging therapy and thrombectomy alone in patients with large infarcts of unrestricted size: LASTE trial post hoc analysis. J Neurointerv Surg. 2026 Mar 6:jnis-2025-024872. doi: 10.1136/jnis-2025-024872. Online ahead of print.
PubMed 41791871Costalat V, Lapergue B, Albucher JF, Labreuche J, Henon H, Gory B, Sibon I, Boulouis G, Cognard C, Nouri N, Richard S, Marnat G, Di Maria F, Annan M, Duhamel A, Cagnazzo F, Jovin T, Arquizan C; LASTE Trial Investigators. Evaluation of acute mechanical revascularization in large stroke (ASPECTS ⩽5) and large vessel occlusion within 7 h of last-seen-well: The LASTE multicenter, randomized, clinical trial protocol. Int J Stroke. 2024 Jan;19(1):114-119. doi: 10.1177/17474930231191033. Epub 2023 Jul 31.
PubMed 37462028
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Acute Mechanical Revascularisation in Large Stroke (ASPECTS 0-5) With Large Vessel Occlusion Within 7 Hours After Stroke Onset or Last Known Well
- ClinicalTrials.gov ID
- NCT03811769
- Acronym / sponsor ID
- LASTE / RECHMPL18_0173
- Conditions
- Stroke
- Keywords
- Mechanical thrombectomy, Stroke, Proximal intracranial arterial occlusions, Large vessel occlusion
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Although the planned sample size was 450, enrollment was halted early following an unplanned interim analysis recommended by the Data Safety Monitoring Board because results favoring thrombectomy were reported from other similar trials.
- Enrolment
- 335 participants (actual)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Study start
- 7 Apr 2019 (actual)
- Primary completion
- 26 Apr 2023 (actual)
- Study completion
- 24 Aug 2023 (actual)
- First posted
- 22 Jan 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Stroke represents the fourth leading cause of death in industrialized nations, after heart disease, cancer, and chronic lower respiratory disease. The overall burden of stroke will rise dramatically in the next 20 years due to an ageing population. Approximately one-quarter of the patients suffering a stroke die within one year after the initial event and stroke is a leading cause of serious long-term disability. Acute ischemic stroke (AIS) due to large vessel occlusion (LVO) is a potentially devastating event, with a poor prognosis in the absence of timely revascularization. Whether in patients with large anterior circulation stroke, direct mechanical intervention is equally effective, superior or inferior to bridging thrombolysis remains a matter of debate.
Thus, this procedure, is now the recommended standard of care for selective patients with LVO in the anterior circulation. When performed with newer generation devices (mainly stent retrievers), more stringent imaging selection criteria and more efficient workflow than in previous trials, significantly reduces disability rates after AIS caused by LVO in the anterior circulation.
The STAIR (Stroke Treatment Academic Industry Roundtable) meeting aims to advance acute stroke therapy development through collaboration between academia, industry, and regulatory institutions. In pursuit of this goal and building on the available level I evidence of benefit from endovascular therapy (EVT) in large vessel occlusion stroke, STAIR IX consensus recommendations were developed that outline priorities for future research in EVT.
Detailed description
The LASTE hypothesis is that patient harbouring a large ischemic core stroke at presentation, may still benefit from mechanical thrombectomy, given the very poor natural history of patient managed by a standalone medical therapy.
The threshold of ASPECTS 5 to set a benefit for treatment was inspired by initial large medical trials using IV t-PA25-27 (Samurai-CT ALBERTA Score IV cohort). In the paradigm of acute and complete reperfusion, radiographic infarct stroke volume may be partially reversible and thus the resulting final infarct may be smaller compared to the one in non-re-perfused patients who will consequently have poorer clinical outcomes. By now, large core patients defined as ASPECTS 0-5 were excluded from most randomized clinical trials resulting in a lack of unequivocal evidence of benefit in this patient population.
Analyses of several prospective cohorts suggest signals of benefit in favor of thrombectomy in patients with large baseline core. In the prospective cohort ETIS, LAPERGUE et al reported a rate of good outcome of 34% in the subgroup of patient with ASPECT 4-5. In the prospective cohort analysis RECOST, a mean mRS score of 34% in a group of patient presenting ASPECT 0-5 treated with mechanical thrombectomy, versus 9% of good outcome in the medical group, suggesting a benefit to treat LVO harbouring a large core. The strongest argument in favor of benefit of EVT even in patients with large core is provided by the six completed randomized endovascular stroke trials. These trials did prove that Combined Approach Mechanical + IV t-PA, is superior to standalone IV lytics, mRs score ≤ 2 ranging from 33% and up to 72%, but Large Core Infarction were largely excluded. Nonetheless a pooled analysis of these trials revealed that a minority of patients with large baseline core were still randomized. In MR CLEAN study, despite no exclusion criteria defined in the initial protocol, the median ASPECT score of the cohort was 9 out of 10. In SWIFT-PRIME study, the mean ASPECT score of the cohort was 7, and in REVASCAT study it was 6.8.
The LASTE protocol "Large Stroke Therapy Evaluation" aims to study the efficacy and safety of mechanical thrombectomy in the acute phase of cerebral infarction less than 7 hours for patients with a large volume of necrosis defined by a score ASPECT from 0 to 5. The patients will be followed 6 months after the stroke.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Best Medical Therapy (BMT) | Other | Other: Best Medical TherapyBest treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration |
| Mechanical Thrombectomy (MT) | Other | Procedure: Mechanical ThrombectomyEndovascular treatment (thrombectomy) associated with the best medical treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Subject is ≥ 18 years old at inclusion (no upper age limit)
- Clinical signs consistent with acute ischemic stroke with symptoms onset or TLKW ≤ 6.5 hours from randomization, or with negative FLAIR on MRI if TLSW is unknown, with treatment started within 7 hours.
- Proven Large Ischemic Core defined as: ASPECT Score ≤ 5 on non-contrast CT or DWI-MRI, and in patients ≥ 80 years: ASPECT = 3 to 5 on non-contrast CT or DWI-MRI
- Proved anterior circulation intracranial large vessel occlusion on CTA or MRA (intracranial ICA, M1, M1-M2). The MCA - M1 segment is defined as the first branch of the intracranial ICA which courses horizontally from its branching point off the ICA through the Sylvian fissure up to the first bifurcation distal to the lenticulo-striate arteries, in the Sylvian fissure. M2 is defined as the portions of the MCA distal to the first bifurcation or trifurcation, but prior to the second bifurcation.
- Patient or patient's representative has received information about the study and has signed and dated the appropriate Informed Consent Form
Key exclusion criteria (26 listed)
- Known absence of vascular access.
- Known contrast or endovascular product life-threatening allergy.
- Female who is known to be pregnant or lactating at time of admission
- Patient presents severe or fatal co-morbidities or life expectancy under 6 months that will likely interfere with the improvement or follow-up or that will render the procedure unlikely to benefit the patient.
- Patient unable to present or be available for follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Best Medical TherapyThe administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies. | Other | Best Medical Therapy (BMT) |
| Mechanical ThrombectomyMT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access). | Procedure or surgery | Mechanical Thrombectomy (MT) |
Primary outcome
Evaluation of patient's condition
Time frame: 3 months
Shift on the mRS at 90 days in experimental group vs the control group
8 secondary outcomes
Evaluation of patient's condition
Time frame: 6 months
Evaluation of good functional outcome
Time frame: 3 and 6 months
Evaluation of functional outcome
Time frame: 3 and 6 months
Evaluation of treatment effect
Time frame: 3 and 6 months
Evaluation of quality of life
Time frame: 3 and 6 months
Evaluation of decompressive condition
Time frame: 7 days
Evaluation of medical response
Time frame: Day 5-7 or discharge, whichever is earlier
Evaluation of medical condition
Time frame: 1 day
Results and safety
The study was stopped early (reason given: Although the planned sample size was 450, enrollment was halted early following an unplanned interim analysis recommended by the Data Safety Monitoring Board because results favoring thrombectomy were reported from other similar trials.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2025.
- Background: PubMed 2314063Cody JT. Cross-reactivity of amphetamine analogues with Roche Abuscreen radioimmunoassay reagents. J Anal Toxicol. 1990 Jan-Feb;14(1):50-3. doi: 10.1093/jat/14.1.50.
- Results publication: PubMed 38718358Costalat V, Jovin TG, Albucher JF, Cognard C, Henon H, Nouri N, Gory B, Richard S, Marnat G, Sibon I, Di Maria F, Annan M, Boulouis G, Cardona P, Obadia M, Piotin M, Bourcier R, Guillon B, Godard S, Pasco-Papon A, Eker OF, Cho TH, Turc G, Naggara O, Velasco S, Lamy M, Clarencon F, Alamowitch S, Renu A, Suissa L, Brunel H, Gentric JC, Timsit S, Lamy C, Chivot C, Macian-Montoro F, Mounayer C, Ozkul-Wermester O, Papagiannaki C, Wolff V, Pop R, Ferrier A, Chabert E, Ricolfi F, Bejot Y, Lopez-Cancio E, Vega P, Spelle L, Denier C, Millan M, Arenillas JF, Mazighi M, Houdart E, Del Mar Freijo M, Duhamel A, Sanossian N, Liebeskind DS, Labreuche J, Lapergue B, Arquizan C; LASTE Trial Investigators. Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size. N Engl J Med. 2024 May 9;390(18):1677-1689. doi: 10.1056/NEJMoa2314063.
- Derived from this study: PubMed 41979451Lapergue B, Arquizan C, Albucher JF, Cognard C, Henon H, Nouri N, Gory B, Richard S, Marnat G, Sibon I, Di Maria F, Annan M, Boulouis G, Cardona P, Labreuche J, Costalat V, Jovin TG; LASTE Trial Investigators. Endovascular Thrombectomy in Patients With Largest Baseline Infarcts (ASPECTS 0-2): An Ancillary Analysis of the LASTE Trial. Stroke. 2026 Jun;57(6):1504-1512. doi: 10.1161/STROKEAHA.125.054161. Epub 2026 Apr 14.
- Derived from this study: PubMed 41791871Gerschenfeld G, Lapergue B, Labreuche J, Albucher JF, Cognard C, Henon H, Nouri N, Richard S, Gory B, Sibon I, Marnat G, Van Dokkum L, Liebeskind DS, Jovin TG, Costalat V, Alamowitch S, Arquizan C; LASTE Trial Investigators. Efficacy and safety of bridging therapy and thrombectomy alone in patients with large infarcts of unrestricted size: LASTE trial post hoc analysis. J Neurointerv Surg. 2026 Mar 6:jnis-2025-024872. doi: 10.1136/jnis-2025-024872. Online ahead of print.
- Derived from this study: PubMed 37462028Costalat V, Lapergue B, Albucher JF, Labreuche J, Henon H, Gory B, Sibon I, Boulouis G, Cognard C, Nouri N, Richard S, Marnat G, Di Maria F, Annan M, Duhamel A, Cagnazzo F, Jovin T, Arquizan C; LASTE Trial Investigators. Evaluation of acute mechanical revascularization in large stroke (ASPECTS ⩽5) and large vessel occlusion within 7 h of last-seen-well: The LASTE multicenter, randomized, clinical trial protocol. Int J Stroke. 2024 Jan;19(1):114-119. doi: 10.1177/17474930231191033. Epub 2023 Jul 31.
Related trials for Stroke
RecruitingObservational study
Natural History of Stroke: Cause and Development
Brain Disease, Ischemic Attack, Transient
RecruitingPhase 4
Xeomin® and Gait Related Mobility After Stroke
Stroke
Active, not recruitingPhase 3
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Intracranial Arteriosclerosis, Stroke
Recruiting
Impact of Atrial Fibrosis Surface Area on the Occurrence of Atrial Fibrillation in Patients With Ischemic Stroke of Undetermined Origin: a Prospective Cardiac MRI Pilot Study.
Stroke, Implantation of an Implantable Cardiac Monitor
Recruiting
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
Brainstem Stroke, ALS
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vincent COSTALAT, PU-PH principal investigator
Hôpital Gui de Chauliac
Caroline ARQUIZAN, PH principal investigator
Hôpital Gui de Chauliac
Bertrand LAPERGUE principal investigator
Hôpital Foch
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Best Medical Therapy and Mechanical Thrombectomy in people with Stroke, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 29 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Although the planned sample size was 450, enrollment was halted early following an unplanned interim analysis recommended by the Data Safety Monitoring Board because results favoring thrombectomy were reported from other similar trials.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of patient's condition (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03811769, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2025; AzTrials last refreshed its copy on 27 Oct 2026.